TY - JOUR
T1 - PRMT3-mediated post-translational adaptation to fasting regulates metabolic flexibility
AU - Huang, Zhengyun
AU - Liu, Xiangpeng
AU - Chen, Xiyue
AU - Zhou, You
AU - Chen, Qian
AU - Liu, Yan
AU - Zhu, Hongyun
AU - Cheng, Ken
AU - Feng, Yu
AU - Dong, Miren
AU - Song, Linsheng
AU - Wang, Lingling
AU - Liu, Shiqi
AU - Shan, Tizhong
AU - Kuang, Shihuan
AU - Dong, Yingying
AU - Vidal-Puig, Antonio
AU - Zhang, Yong
AU - Jia, Zhihao
N1 - Publisher Copyright:
© 2026. The Author(s).
PY - 2026/2/2
Y1 - 2026/2/2
N2 - Obesity impairs metabolic flexibility-the capacity to adapt to fluctuating energy demands. Emerging evidence suggests that dietary interventions, particularly time-restricted feeding (TRF), may help restore this flexibility. In this study, we demonstrate that feeding upregulates PRMT3 and asymmetric dimethylarginine (ADMA)-containing proteins via insulin-pAKT signaling, while fasting reduces their expression. Pharmacological inhibition of PRMT3 attenuates diet-induced obesity (DIO) and enhances adipocyte glycolysis in male mice. Mechanistically, PRMT3 drives the expression of citrate transporter SLC25A1 during feeding through direct arginine methylation. A 16:8 TRF regimen normalizes PRMT3 and ADMA levels while suppressing SLC25A1 expression. Notably, PRMT3 inhibition recapitulates the metabolic benefits of 16:8 TRF and improves metabolic flexibility. Furthermore, adipocyte-specific deletion of Slc25a1 in male mice protects against DIO and enhances insulin sensitivity. Collectively, these findings identify PRMT3-mediated arginine methylation in vWAT as a nutrient-responsive regulatory axis that impairs metabolic flexibility in obesity, which is a potential therapeutic target.
AB - Obesity impairs metabolic flexibility-the capacity to adapt to fluctuating energy demands. Emerging evidence suggests that dietary interventions, particularly time-restricted feeding (TRF), may help restore this flexibility. In this study, we demonstrate that feeding upregulates PRMT3 and asymmetric dimethylarginine (ADMA)-containing proteins via insulin-pAKT signaling, while fasting reduces their expression. Pharmacological inhibition of PRMT3 attenuates diet-induced obesity (DIO) and enhances adipocyte glycolysis in male mice. Mechanistically, PRMT3 drives the expression of citrate transporter SLC25A1 during feeding through direct arginine methylation. A 16:8 TRF regimen normalizes PRMT3 and ADMA levels while suppressing SLC25A1 expression. Notably, PRMT3 inhibition recapitulates the metabolic benefits of 16:8 TRF and improves metabolic flexibility. Furthermore, adipocyte-specific deletion of Slc25a1 in male mice protects against DIO and enhances insulin sensitivity. Collectively, these findings identify PRMT3-mediated arginine methylation in vWAT as a nutrient-responsive regulatory axis that impairs metabolic flexibility in obesity, which is a potential therapeutic target.
UR - https://www.scopus.com/pages/publications/105032700077
U2 - 10.1038/s41467-026-68883-6
DO - 10.1038/s41467-026-68883-6
M3 - Article
C2 - 41629293
AN - SCOPUS:105032700077
SN - 2041-1723
VL - 17
JO - Nature Communications
JF - Nature Communications
IS - 1
ER -